Changes to the Code
S. 891 · Bipartisan Health Care Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
2 U.S.C. § 901a Enforcement of budget goal
2 changes the bill asks for here, 1 carried out
- Not carried out:
in subparagraph (D), by striking
such that,
and all that follows and insertingsuch that the payment reduction shall be 2.0 percent.
; and“such that,” isn't in § 901a(6)(D) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“such that,” not found in /us/usc/t2/s901a/6/D - Carried out:
by adding at the end the following:
(F) On the date on which the President submits the budget under section 1105 of title 31, United States Code, for fiscal year 2033, the President shall order a sequestration of payments for the Medicare programs specified in section 256(d), effective upon issuance, such that, …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 901a(6)–(8)
Start of § 901a to (6)(F) unchanged ·
(i) with respect to the first 5 months in which such order is effective for such fiscal year, the payment reduction shall be 2.0 percent; and
(ii) with respect to the last 7 months in which such order is effective for such fiscal year, the payment reduction shall be 0 percent.
(F) [inserted: On the date on which the President submits the budget under section 1105 of title 31, United States Code, for fiscal year 2033, the President shall order a sequestration of payments for the Medicare programs specified in section 256(d), effective upon issuance, such that, notwithstanding the 2 percent limit specified in subparagraph (A) for such payments—]
(i) [inserted: with respect to the first 2 months in which such order is effective for such fiscal year, the payment reduction shall be 2.0 percent; and]
(ii) [inserted: with respect to the last 10 months in which such order is effective for such fiscal year, the payment reduction shall be 0 percent.]
(7) Adjustment for Medicare If the percentage reduction for the Medicare programs would exceed 2 percent for a fiscal year in the absence of paragraph (6), OMB shall increase the reduction for all other discretionary appropriations and direct spending under paragraph (4) by a uniform percentage to a level sufficient to achieve the reduction required by paragraph (4) in the non-defense function.
(8) Implementation of reductions Any reductions imposed under this section shall be implemented in accordance with section 906(k) of this title.
Rest of § 901a unchanged ·
21 U.S.C. § 355 New drugs
1 change the bill asks for here, 1 carried out
- Carried out:
Section 505(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(3)) is amended by adding at the end the following:
(H) (i) Upon request (in controlled correspondence or an analogous process) by a person that has submitted or intends to submit an abbreviated application under this subsection for a drug that is required by regulation to contain one or more of the same inactive ingredients in …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 355(j)Abbreviated new drug applications(3)–(4)
Start of § 355 to (j)(3)(H)(iii)(II) unchanged ·
(iv) If the Secretary makes a written determination described in clause (iii)(II), the Secretary shall provide notice and a copy of the written determination to the person making the request under clause (i).
(v) The disclosures authorized under clauses (i) and (ii) are disclosures authorized by law, including for purposes of section 1905 of title 18. This subparagraph shall not otherwise be construed to authorize the disclosure of nonpublic qualitative or quantitative information about the ingredients in a listed drug, or to affect the status, if any, of such information as trade secret or confidential commercial information for purposes of section 331(j) of this title, section 552 of title 5, or section 1905 of title 18.
(H)
(i) [inserted: Upon request (in controlled correspondence or an analogous process) by a person that has submitted or intends to submit an abbreviated application under this subsection for a drug that is required by regulation to contain one or more of the same inactive ingredients in the same concentrations as the listed drug referred to, or for which the Secretary determines there is a scientific justification for an approach that is in vitro, in whole or in part, to be used to demonstrate bioequivalence for a drug if such a drug contains one or more of the same inactive ingredients in the same concentrations as the listed drug referred to, the Secretary shall inform the person whether such drug is qualitatively and quantitatively the same as the listed drug. The Secretary may also provide such information to such a person on the Secretary’s own initiative during the review of an abbreviated application under this subsection for such drug.]
(ii) [inserted: Notwithstanding section 301(j), if the Secretary determines that such drug is not qualitatively or quantitatively the same as the listed drug, the Secretary shall identify and disclose to the person—]
(I) [inserted: the ingredient or ingredients that cause such drug not to be qualitatively or quantitatively the same as the listed drug; and]
(II) [inserted: for any ingredient for which there is an identified quantitative deviation, the amount of such deviation.]
(iii) [inserted: If the Secretary determines that such drug is qualitatively and quantitatively the same as the listed drug, the Secretary shall not change or rescind such determination after the submission of an abbreviated application for such drug under this subsection unless—]
(I) [inserted: the formulation of the listed drug has been changed and the Secretary has determined that the prior listed drug formulation was withdrawn for reasons of safety or effectiveness; or]
(II) [inserted: the Secretary makes a written determination that the prior determination must be changed because an error has been identified.]
(iv) [inserted: If the Secretary makes a written determination described in clause (iii)(II), the Secretary shall provide notice and a copy of the written determination to the person making the request under clause (i).]
(v) [inserted: The disclosures authorized under clauses (i) and (ii) are disclosures authorized by law, including for purposes of section 1905 of title 18, United States Code. This subparagraph shall not otherwise be construed to authorize the disclosure of nonpublic qualitative or quantitative information about the ingredients in a listed drug, or to affect the status, if any, of such information as trade secret or confidential commercial information for purposes of section 301(j) of this Act, section 552 of title 5, United States Code, or section 1905 of title 18, United States Code.]
(4) Subject to paragraph (5), the Secretary shall approve an application for a drug unless the Secretary finds—
(A) the methods used in, or the facilities and controls used for, the manufacture, processing, and packing of the drug are inadequate to assure and preserve its identity, strength, quality, and purity;
Rest of § 355 unchanged ·
21 U.S.C. § 355c Research into pediatric uses for drugs and biological products
11 changes the bill asks for here, 6 carried out
- Carried out:
by redesignating subparagraphs (B) and (C) as subparagraphs (C) and (D), respectively; and
The section already has a provision under this letter or number, so it would have two.
- Carried out:
by striking subparagraph (A) and inserting the following:
(A) In general.— For purposes of paragraph (1)(B), the investigation described in this paragraph is a molecularly targeted pediatric cancer investigation of— (i) the drug or biological product for which the application referred to in such paragraph is submitted; or (ii) such …
- Carried out:
Section 505B(e)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(e)(1)) is amended by adding at the end the following:
The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).
. - Not carried out:
Section 505B(a)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(a)(1)) is amended by adding at the end the following:
(C) Rule of construction.— No application that is subject to the requirements of subparagraph (B) shall be subject to the requirements of subparagraph (A), and no application (or supplement to an application) that is subject to the requirements of subparagraph (A) shall be …
The law already reads this way: § 355c(a)(1)(C) is already as the bill would have it.
Technical detail
already there: /us/usc/t21/s355c/a/1/C reads as the bill would have it - Not carried out:
in paragraph (3)(C), as redesignated by paragraph (1)(A) of this subsection, by striking
investigations described in this paragraph
and insertinginvestigations referred to in subparagraph (A)
; and“investigations described in this paragraph” isn't in § 355c(a)(3)(C) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“investigations described in this paragraph” not found in /us/usc/t21/s355c/a/3/C - Not carried out:
in paragraph (3)(D), as redesignated by paragraph (1)(A) of this subsection, by striking
the assessments under paragraph (2)(B)
and insertingthe assessments required under paragraph (1)(A)
.“the assessments under paragraph (2)(B)” isn't in § 355c(a)(3)(D) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“the assessments under paragraph (2)(B)” not found in /us/usc/t21/s355c/a/3/D~2 - Carried out:
in paragraph (1), by striking
Beginning 270
and insertingNoncompliance letter.—Beginning 270
; - Carried out:
by striking
The drug or
and insertingEffect of noncompliance.—The drug or
; and - Not carried out:
by striking
(except that the drug or biological product shall not be subject to action under section 303)
and inserting(except that the drug or biological product shall be subject to action under section 303 only if such person demonstrated a lack of due diligence in satisfying the applicable requirement)
; and“(except that the drug or biological product shall not be subject to action under section 303)” isn't in § 355c(d)(2) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“(except that the drug or biological product shall not be subject to action under section 303)” not found in /us/usc/t21/s355c/d/2 - Carried out:
by adding at the end the following:
(3) Limitation.— The Secretary shall not issue enforcement actions under section 303 for failures under this subsection in the case of a drug or biological product that is no longer marketed..
The section already has a provision under this letter or number, so it would have two.
- Not carried out:
Section 505B(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(d)), as amended by subsection (a), is further amended by adding at the end the following:
(4) Due diligence.— Before the Secretary may conclude that a person failed to submit or otherwise meet a requirement as described in the matter preceding paragraph (1), the Secretary shall— (A) issue a noncompliance letter pursuant to paragraph (1); (B) provide such person with …
The law already reads this way: § 355c(d)(4) is already as the bill would have it.
Technical detail
already there: /us/usc/t21/s355c/d/4 reads as the bill would have it
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
2 of the 11 changes this bill asks for here are already in the law as it stands, and were not made a second time. The bill, or another making the same changes, has probably become law since.
§ 355c(a)New drugs and biological products(2)–(4)
Start of § 355c to (a)(2)(B)(ii) unchanged ·
(iii) Information on extrapolation A brief documentation of the scientific data supporting the conclusion under clauses (i) and (ii) shall be included in any pertinent reviews for the application under section 355 of this title or section 262 of title 42.
(3) 1 Molecularly targeted pediatric cancer investigation
(A) In general[inserted: .—] For purposes of paragraph (1)(B), the investigation described in this paragraph is a molecularly targeted pediatric cancer investigation of—
(i) the drug or biological product for which the application referred to in such paragraph is submitted; or
(ii) such drug or biological product used in combination with—
(I) an active ingredient of a drug or biological product—
(aa) for which an approved application under section [struck: 355][inserted: 505](j) under this [struck: title][inserted: Act] or under section [struck: 262][inserted: 351](k) of [struck: title][inserted: the] [struck: 42][inserted: Public] [inserted: Health Service Act ]is in effect; and
(bb) that is determined by the Secretary, after consultation with the applicant, to be part of the standard of care for treating a pediatric cancer; or
(II) an active ingredient of a drug or biological product—
(aa) for which an approved application under section [struck: 355][inserted: 505](b) of this [struck: title][inserted: Act] or section [struck: 262][inserted: 351](a) of [struck: title][inserted: the] [struck: 42][inserted: Public] [inserted: Health Service Act ]to treat an adult cancer is in effect and is held by the same person submitting the application under paragraph (1)(B); and
(bb) that is directed at a molecular target that the Secretary determines to be substantially relevant to the growth or progression of a pediatric cancer.
(B) [inserted: Additional requirements.—]
(i) [inserted: Design of investigation.—] [inserted: A molecularly targeted pediatric cancer investigation referred to in subparagraph (A) shall be designed to yield clinically meaningful pediatric study data that is gathered using appropriate formulations for each age group for which the study is required, regarding dosing, safety, and preliminary efficacy to inform potential pediatric labeling.]
(ii) [inserted: Limitation.—] [inserted: An investigation described in subparagraph (A)(ii) may be required only if the drug or biological product for which the application referred to in paragraph (1)(B) contains either—]
(I) [inserted: a single new active ingredient; or]
(II) [inserted: more than one active ingredient, if an application for the combination of active ingredients has not previously been approved but each active ingredient is in a drug product that has been previously approved to treat an adult cancer.]
(iii) [inserted: Results of already-completed preclinical studies of application drug.—] [inserted: With respect to an investigation required pursuant to paragraph (1)(B), the Secretary may require the results of any completed preclinical studies relevant to the initial pediatric study plan be submitted to the Secretary at the same time that the initial pediatric study plan required under subsection (e)(1) is submitted.]
(iv) [inserted: Rule of construction regarding inactive ingredients.—] [inserted: With respect to a combination of active ingredients referred to in subparagraph (A)(ii), such subparagraph shall not be construed as addressing the use of inactive ingredients with such combination.]
[struck: (B)] [inserted: (C)] Additional requirements
(i) Design of investigation A molecularly targeted pediatric cancer investigation referred to in subparagraph (A) shall be designed to yield clinically meaningful pediatric study data that is gathered using appropriate formulations for each age group for which the study is required, regarding dosing, safety, and preliminary efficacy to inform potential pediatric labeling.
(ii) Limitation An investigation described in subparagraph (A)(ii) may be required only if the drug or biological product for which the application referred to in paragraph (1)(B) contains either—
(I) a single new active ingredient; or
(II) more than one active ingredient, if an application for the combination of active ingredients has not previously been approved but each active ingredient is in a drug product that has been previously approved to treat an adult cancer.
(iii) Results of already-completed preclinical studies of application drug With respect to an investigation required pursuant to paragraph (1)(B), the Secretary may require the results of any completed preclinical studies relevant to the initial pediatric study plan be submitted to the Secretary at the same time that the initial pediatric study plan required under subsection (e)(1) is submitted.
(iv) Rule of construction regarding inactive ingredients With respect to a combination of active ingredients referred to in subparagraph (A)(ii), such subparagraph shall not be construed as addressing the use of inactive ingredients with such combination.
[struck: (C)] [inserted: (D)] Extrapolation of data Paragraph (2)(B) shall apply to investigations referred to in subparagraph (A) to the same extent and in the same manner as paragraph (2)(B) applies with respect to the assessments required under paragraph (1)(A).
(D) Deferrals and waivers Deferrals and waivers under paragraphs (4) and (5) shall apply to investigations described in this paragraph to the same extent and in the same manner as such deferrals and waivers apply with respect to the assessments required under paragraph (1)(A).
(4) Deferral
§ 355c(d)Submission of assessments and reports on the investigation(1)–(2)
(a)(4)(A)–(c)(2) unchanged ·
(d) Submission of assessments and reports on the investigation If a person fails to submit a required assessment described in subsection (a)(2) or the investigation described in subsection (a)(3), fails to meet the applicable requirements in subsection (a)(4), or fails to submit a request for approval of a pediatric formulation described in subsection (a) or (b), in accordance with applicable provisions of subsections (a) and (b), the following shall apply:
(1) Noncompliance letter [inserted: Noncompliance letter.—]Beginning 270 days after July 9, 2012, the Secretary shall issue a non-compliance letter to such person informing them of such failure to submit or meet the requirements of the applicable subsection. Such letter shall require the person to respond in writing within 45 calendar days of issuance of such letter. Such response may include the person’s request for a deferral extension if applicable. Such letter and the person’s written response to such letter shall be made publicly available on the Internet Web site of the Food and Drug Administration 60 calendar days after issuance, with redactions for any trade secrets and confidential commercial information. If the Secretary determines that the letter was issued in error, the requirements of this paragraph shall not apply. The Secretary shall inform the Pediatric Advisory Committee of letters issued under this paragraph and responses to such letters.
(2) Effect of noncompliance [inserted: Effect of noncompliance.—]The drug or biological product that is the subject of an assessment described in subsection (a)(2) or the investigation described in subsection (a)(3), applicable requirements in subsection (a)(4), or request for approval of a pediatric formulation, may be considered misbranded solely because of that failure and subject to relevant enforcement action (except that the drug or biological product shall be subject to action under section 333 of this title only if such person demonstrated a lack of due diligence in satisfying the applicable requirement), but such failure shall not be the basis for a proceeding—
(A) to withdraw approval for a drug under section 355(e) of this title; or
(B) to revoke the license for a biological product under section 262 of title 42.
§ 355c(d)–(e)
(d)(3)–(4) unchanged ·
(B) provide such person with a 45-day period beginning on the date of receipt of such noncompliance letter to respond in writing as set forth in such paragraph; and
(C) after reviewing such written response, determine whether the person demonstrated a lack of due diligence in satisfying such requirement.
(3) [inserted: Limitation.—] [inserted: The Secretary shall not issue enforcement actions under section 303 for failures under this subsection in the case of a drug or biological product that is no longer marketed.]
(e) Pediatric study plans
(1) In general An applicant subject to subsection (a) shall submit to the Secretary an initial pediatric study plan prior to the submission of the assessments described under subsection (a)(2) or the investigation described in subsection (a)(3). The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).1[inserted: The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).]
(2) Timing; content; meetings
(A) Timing An applicant shall submit the initial pediatric study plan under paragraph (1)—
Rest of § 355c unchanged ·
21 U.S.C. § 355c–1 Report
4 changes the bill asks for here, 2 carried out
- Carried out:
in paragraph (11), by striking the semicolon at the end and inserting , including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions
;
; - Not carried out:
in paragraph (15), by striking
and
at the end;The bill strikes “and” at the end of § 355c–1(b)(15), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“and” is not at the end of /us/usc/t21/s355c–1/b/15 - Not carried out:
in paragraph (16), by striking the period at the end and inserting
; and
; andThe bill strikes “.” at the end of § 355c–1(b)(16), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“.” is not at the end of /us/usc/t21/s355c–1/b/16 - Carried out:
by adding at the end the following:
(17) a listing of penalties, settlements, or payments under section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353) for failure to comply with requirements under such section 505B, including, for each penalty, settlement, or payment, the name of the drug, the …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 355c–1(b)Contents(10)–(12)
Start of § 355c–1 to (b)(9) unchanged ·
(10) an assessment of the successes of and limitations to studying drugs for rare diseases under such sections 355a and 355c of this title;
(11) an assessment of the impact of the amendments to such section 355c of this title made by the FDA Reauthorization Act of 2017 on pediatric research and labeling of drugs and biological products and pediatric labeling of molecularly targeted drugs and biological products for the treatment of cancer, including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions[inserted: , including an evaluation of compliance with deadlines provided for in deferrals and deferral extensions];
(12) an assessment of the efforts of the Secretary to implement the plan developed under section 505C–1 of the Federal Food, Drug, and Cosmetic Act,1 regarding earlier submission of pediatric studies under sections 355a and 355c of this title and section 262(m) of title 42, including—
(A) the average length of time after the approval of an application under section 355(b)(1) of this title or section 262(a) of title 42 before studies conducted pursuant to such section 355a of this title, 355c of this title, or section 262(m) of title 42 are completed, submitted, and incorporated into labeling;
§ 355c–1(b)–(c)
(b)(12)(B)–(15) unchanged ·
(16) the Secretary’s assessment of the overall impact of the amendments made by section 504 of the FDA Reauthorization Act of 2017 on the conduct and effectiveness of pediatric cancer research and the orphan drug program, as well any subsequent recommendations; and
(17) a listing of penalties, settlements, or payments under section 333 of this title for failure to comply with requirements under such section 355c of this title, including, for each penalty, settlement, or payment, the name of the drug, the sponsor thereof, and the amount of the penalty, settlement, or payment imposed.
(17) [inserted: a listing of penalties, settlements, or payments under section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353) for failure to comply with requirements under such section 505B, including, for each penalty, settlement, or payment, the name of the drug, the sponsor thereof, and the amount of the penalty, settlement, or payment imposed; and]
(c) Stakeholder comment At least 180 days prior to the submission of each report under subsection (a), the Secretary shall consult with representatives of patient groups (including pediatric patient groups), consumer groups, regulated industry, academia, and other interested parties to obtain any recommendations or information relevant to the report including suggestions for modifications that would improve pediatric drug research and pediatric labeling of drugs and biological products.
21 U.S.C. § 360cc Protection for drugs for rare diseases or conditions
5 changes the bill asks for here, 1 carried out
- Not carried out:
in subsection (a), in the matter following paragraph (2), by striking
same disease or condition
and insertingsame approved use or indication within such rare disease or condition
;“same disease or condition” isn't in § 360cc(a) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“same disease or condition” not found in /us/usc/t21/s360cc/a - Not carried out:
in the matter preceding paragraph (1), by striking
same rare disease or condition
and insertingsame approved use or indication for which such 7-year period applies to such already approved or licensed drug
; and“same rare disease or condition” isn't in § 360cc(b) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“same rare disease or condition” not found in /us/usc/t21/s360cc/b - Not carried out:
in paragraph (1), by inserting
, relating to the approved use or indication,
afterthe needs
;The law already reads this way: § 360cc(b)(1) already has “, relating to the approved use or indication,”.
Technical detail
already reads “, relating to the approved use or indication,” at that place in /us/usc/t21/s360cc/b/1 - Not carried out:
in subsection (c)(1), by striking
same rare disease or condition as the already approved drug
and insertingsame use or indication for which the already approved or licensed drug was approved or licensed
; and“same rare disease or condition as the already approved drug” isn't in § 360cc(c)(1) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“same rare disease or condition as the already approved drug” not found in /us/usc/t21/s360cc/c/1 - Carried out:
by adding at the end the following:
(f) Approved use or indication defined.— In this section, the term “approved use or indication” means the use or indication approved under section 505 of this Act or licensed under section 351 of the Public Health Service Act for a drug designated under section 526 for a rare disease or condition..
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
1 of the 5 changes this bill asks for here is already in the law as it stands, and was not made a second time. The bill, or another making the same changes, has probably become law since.
§ 360cc(e)–(f)
Start of § 360cc to (e)(1) unchanged ·
(2) upon granting exclusive approval or licensure under subsection (a) on the basis of a demonstration of clinical superiority as described in subsection (c), shall publish a summary of the clinical superiority findings.
(f) Approved use or indication defined In this section, the term “approved use or indication” means the use or indication approved under section 355 of this title or licensed under section 262 of title 42 for a drug designated under section 360bb of this title for a rare disease or condition.
(f) [inserted: Approved use or indication defined.—] [inserted: In this section, the term “approved use or indication” means the use or indication approved under section 505 of this Act or licensed under section 351 of the Public Health Service Act for a drug designated under section 526 for a rare disease or condition.]
21 U.S.C. § 360ff Priority review to encourage treatments for rare pediatric diseases
2 changes the bill asks for here, 1 carried out
- Not carried out:
Paragraph (5) of section 529(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff(b)) is amended by striking
December 20, 2024, unless
and all that follows through the period at the end and insertingSeptember 30, 2029.
.“December 20, 2024, unless” isn't in § 360ff(b)(5) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“December 20, 2024, unless” not found in /us/usc/t21/s360ff/b/5 - Carried out:
Section 529(c)(4) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff(c)(4)) is amended by striking subparagraph (A) and inserting the following:
(A) In general.— The priority review user fee required by this subsection shall be due upon the submission of a human drug application under section 505(b)(1) or section 351(a) of the Public Health Service Act for which the priority review voucher is used. All other user fees …
§ 360ff(c)Priority review user fee(3)–(4)
Start of § 360ff to (c)(2)(B) unchanged ·
(3) Annual fee setting The Secretary shall establish, before the beginning of each fiscal year beginning after September 30, 2012, the amount of the priority review user fee for that fiscal year.
(4) Payment
(A) In general[inserted: .—] The priority review user fee required by this subsection shall be due upon the submission of a human drug application under section [struck: 355][inserted: 505](b)(1) [struck: of this title ]or section 351(a) of the Public Health Service Act [struck: [42 U.S.C. 262(a)] ]for which the priority review voucher is used. All other user fees associated with the human drug application shall be due as required by the Secretary or under applicable law.
(B) Complete application An application described under subparagraph (A) for which the sponsor requests the use of a priority review voucher shall be considered incomplete if the fee required by this subsection and all other applicable user fees are not paid in accordance with the Secretary’s procedures for paying such fees.
(C) No waivers, exemptions, reductions, or refunds The Secretary may not grant a waiver, exemption, reduction, or refund of any fees due and payable under this section.
Rest of § 360ff unchanged ·
21 U.S.C. § 360bbb–4a Priority review to encourage treatments for agents that present national security threats
1 change the bill asks for here, 1 carried out
- Carried out:
Section 565A(g) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–4a) is amended by striking
October 1, 2023
and insertingDecember 31, 2026
.
§ 360bbb–4a(f)–(g)
Start of § 360bbb–4a to (e) unchanged ·
(f) Relation to other provisions The provisions of this section shall supplement, not supplant, any other provisions of this chapter or the Public Health Service Act [42 U.S.C. 201 et seq.] that encourage the development of medical countermeasures.
(g) Sunset The Secretary may not award any priority review vouchers under subsection (b) after [struck: October][inserted: December] [struck: 1][inserted: 31], [struck: 2023][inserted: 2026].
21 U.S.C. § 829a Delivery of a controlled substance by a pharmacy to an administering practitioner
1 change the bill asks for here, 1 carried out
- Carried out:
Section 309A(a) of the Controlled Substances Act (21 U.S.C. 829a(a)) is amended by striking paragraph (2) and inserting the following:
(2) the controlled substance is a drug in schedule III, IV, or V to be administered— (A) by injection or implantation for the purpose of maintenance or detoxification treatment; or (B) subject to a risk evaluation and mitigation strategy pursuant to section 505–1 of the Federal …
§ 829a(a)In general(2)–(4)
Start of § 829a to (a)(2) unchanged ·
(A) by injection or implantation for the purpose of maintenance or detoxification treatment; or
(B) subject to a risk evaluation and mitigation strategy pursuant to section [struck: 355][inserted: 505]–1 of [struck: this][inserted: the] [struck: title][inserted: Federal] [inserted: Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) ]that includes elements to assure safe use of the drug described in subsection (f)(3)(E) of such section, including a requirement for post-administration monitoring by a health care provider[struck: ;][inserted: .]
(3) the pharmacy and the practitioner are authorized to conduct the activities specified in this section under the law of the State in which such activities take place;
(4) the prescription is not issued to supply any practitioner with a stock of controlled substances for the purpose of general dispensing to patients;
Rest of § 829a unchanged ·
29 U.S.C. § 1108 Exemptions from prohibited transactions
12 changes the bill asks for here, 5 carried out
- Carried out:
by redesignating subclauses (II) through (IV) as subclauses (III) through (V), respectively;
The section already has a provision under this letter or number, so it would have two.
- Not carried out:
by striking
subclause (II)
and insertingsubclause (III)
; and“subclause (II)” isn't in § 1108(b)(2)(B)(viii)(I) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“subclause (II)” not found in /us/usc/t29/s1108/b/2/B/viii/I - Not carried out:
by striking
subclauses (II) and (III)
and insertingsubclauses (III) and (IV)
; and“subclauses (II) and (III)” isn't in § 1108(b)(2)(B)(viii)(I) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“subclauses (II) and (III)” not found in /us/usc/t29/s1108/b/2/B/viii/I - Carried out:
by inserting after subclause (I) the following:
(II) Pursuant to subsection (a), subparagraphs (C) and (D) of section 406(a)(1) shall not apply to a responsible plan fiduciary, notwithstanding any failure to remit required amounts under subparagraph (C)(i), if the following conditions are met: (aa) The responsible plan …
- Carried out:
by adding at the end the following:
(C) (i) (I) For plan years beginning on or after the date that is 30 months after the date of enactment of this subparagraph (referred to in this clause as the “effective date”), no contract or arrangement or renewal or extension of a contract or arrangement, entered into on or …
The section already has a provision under this letter or number, so it would have two.
- Not carried out:
in subitem (AA) by striking
Brokerage services,
and insertingServices (including brokerage services),
; and“Brokerage services,” isn't in § 1108(b)(2)(B)(ii)(I)(bb)(AA) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“Brokerage services,” not found in /us/usc/t29/s1108/b/2/B/ii/I/bb/AA - Not carried out:
by striking
Consulting,
and insertingOther services,
; and“Consulting,” isn't in § 1108(b)(2)(B)(ii)(I)(bb)(BB) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“Consulting,” not found in /us/usc/t29/s1108/b/2/B/ii/I/bb/BB - Not carried out:
by striking
related to the development or implementation of plan design
and all that follows through the period at the end and insertingincluding any of the following: plan design, insurance or insurance product selection (including vision and dental), recordkeeping, medical management, benefits administration selection (including vision and dental), stop-loss insurance, pharmacy benefit management services, wellness design and management services, transparency tools, group purchasing organization agreements and services, participation in and services from preferred vendor panels, disease management, compliance services, employee assistance programs, or third-party administration services, or consulting services related to any such services.
.“related to the development or implementation of plan design” isn't in § 1108(b)(2)(B)(ii)(I)(bb)(BB) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“related to the development or implementation of plan design” not found in /us/usc/t29/s1108/b/2/B/ii/I/bb/BB - Not carried out:
by striking
requirements of this clause
and insertingrequirements of this subparagraph
; and“requirements of this clause” isn't in § 1108(b)(2)(B)(i) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“requirements of this clause” not found in /us/usc/t29/s1108/b/2/B/i - Carried out:
by adding at the end the following:
For purposes of applying section 406(a)(1)(C) with respect to a transaction described under this subparagraph or subparagraph (C), a contract or arrangement for services between a covered plan and an entity providing services to the plan, including a health insurance issuer providing health insurance coverage in connection with the covered plan, in which such entity contracts, in connection with such plan, with a service provider for pharmacy benefit management services, shall be considered an indirect furnishing of goods, services, or facilities between the covered plan and the service provider for pharmacy benefit management services acting as the party in interest.
. - Carried out:
Section 408(b)(2)(B)(ii)(I)(aa) of such Act (29 U.S.C. 1108(b)(2)(B)(ii)(I)(aa)) is amended by inserting before the period at the end
and the terms health insurance coverage and health insurance issuer have the meanings given such terms in section 733(b)
.
- Not carried out:
Section 408(b)(2)(B)(ii)(I)(aa) of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1108(b)(2)(B)(ii)(I)(aa)) is amended by inserting
in
afterdefined
.The law already reads this way: § 1108(b)(2)(B)(ii)(I)(aa) already has “in”.
Technical detail
already reads “in” at that place in /us/usc/t29/s1108/b/2/B/ii/I/aa
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
1 of the 12 changes this bill asks for here is already in the law as it stands, and was not made a second time. The bill, or another making the same changes, has probably become law since.
§ 1108(b)(2)(A)–(B)
Start of § 1108 to (b)(2) unchanged ·
(A) Contracting or making reasonable arrangements with a party in interest for office space, or legal, accounting, or other services necessary for the establishment or operation of the plan, if no more than reasonable compensation is paid therefor.
(B)
(i) No contract or arrangement for services between a covered plan and a covered service provider, and no extension or renewal of such a contract or arrangement, is reasonable within the meaning of this paragraph unless the requirements of this subparagraph are met. For purposes of applying section 1106(a)(1)(C) of this title with respect to a transaction described under this subparagraph or subparagraph (C), a contract or arrangement for services between a covered plan and an entity providing services to the plan, including a health insurance issuer providing health insurance coverage in connection with the covered plan, in which such entity contracts, in connection with such plan, with a service provider for pharmacy benefit management services, shall be considered an indirect furnishing of goods, services, or facilities between the covered plan and the service provider for pharmacy benefit management services acting as the party in interest.[inserted: For purposes of applying section 406(a)(1)(C) with respect to a transaction described under this subparagraph or subparagraph (C), a contract or arrangement for services between a covered plan and an entity providing services to the plan, including a health insurance issuer providing health insurance coverage in connection with the covered plan, in which such entity contracts, in connection with such plan, with a service provider for pharmacy benefit management services, shall be considered an indirect furnishing of goods, services, or facilities between the covered plan and the service provider for pharmacy benefit management services acting as the party in interest.]
(ii)
(I) For purposes of this subparagraph:
(aa) The term “covered plan” means a group health plan as defined in section 1191b(a) of this title and the terms “health insurance coverage” and “health insurance issuer” have the meanings given such terms in section 1191b(b) of this title[inserted: and the terms health insurance coverage and health insurance issuer have the meanings given such terms in section 733(b)].
(bb) The term “covered service provider” means a service provider that enters into a contract or arrangement with the covered plan and reasonably expects $1,000 (or such amount as the Secretary may establish in regulations to account for inflation since December 27, 2020, as appropriate) or more in compensation, direct or indirect, to be received in connection with providing one or more of the following services, pursuant to the contract or arrangement, regardless of whether such services will be performed, or such compensation received, by the covered service provider, an affiliate, or a subcontractor:
(AA) Services (including brokerage services), for which the covered service provider, an affiliate, or a subcontractor reasonably expects to receive indirect compensation or direct compensation described in item (dd), provided to a covered plan with respect to selection of insurance products (including vision and dental), recordkeeping services, medical management vendor, benefits administration (including vision and dental), stop-loss insurance, pharmacy benefit management services, wellness services, transparency tools and vendors, group purchasing organization preferred vendor panels, disease management vendors and products, compliance services, employee assistance programs, or third party administration services.
§ 1108(b)(2)(B)(viii)–(ix)
(b)(2)(B)(ii)(I)(bb)(BB)–(viii)(I)(aa) unchanged ·
(bb) The responsible plan fiduciary, upon discovering that the covered service provider failed to disclose the required information, requests in writing that the covered service provider furnish such information.
(cc) If the covered service provider fails to comply with a written request described in subclause (III) within 90 days of the request, the responsible plan fiduciary notifies the Secretary of the covered service provider’s failure, in accordance with subclauses (III) and (IV).
(II) [inserted: Pursuant to subsection (a), subparagraphs (C) and (D) of section 406(a)(1) shall not apply to a responsible plan fiduciary, notwithstanding any failure to remit required amounts under subparagraph (C)(i), if the following conditions are met:]
(aa) [inserted: The responsible plan fiduciary did not know that the covered service provider failed or would fail to make required remittances and reasonably believed that the covered service provider remitted such required amounts.]
(bb) [inserted: The responsible plan fiduciary, upon discovering that the covered service provider failed to remit the required amounts, requests in writing that the covered service provider remit such amounts.]
(cc) [inserted: If the covered service provider fails to comply with a written request described in subclause (III) within 90 days of the request, the responsible plan fiduciary notifies the Secretary of the covered service provider’s failure, in accordance with subclauses (III) and (IV).]
[struck: (II)] [inserted: (III)] Pursuant to subsection (a), subparagraphs (C) and (D) of section 1106(a)(1) of this title shall not apply to a responsible plan fiduciary, notwithstanding any failure to remit required amounts under subparagraph (C)(i), if the following conditions are met:
(aa) The responsible plan fiduciary did not know that the covered service provider failed or would fail to make required remittances and reasonably believed that the covered service provider remitted such required amounts.
(bb) The responsible plan fiduciary, upon discovering that the covered service provider failed to remit the required amounts, requests in writing that the covered service provider remit such amounts.
(cc) If the covered service provider fails to comply with a written request described in subclause (III) within 90 days of the request, the responsible plan fiduciary notifies the Secretary of the covered service provider’s failure, in accordance with subclauses (III) and (IV).
[struck: (III)] [inserted: (IV)] A notice described in subclause (I)(cc) shall contain—
(aa) the name of the covered plan;
(bb) the plan number used for the annual report on the covered plan;
(cc) the plan sponsor’s name, address, and employer identification number;
(dd) the name, address, and telephone number of the responsible plan fiduciary;
(ee) the name, address, phone number, and, if known, employer identification number of the covered service provider;
(ff) a description of the services provided to the covered plan;
(gg) a description of the information that the covered service provider failed to disclose;
(hh) the date on which such information was requested in writing from the covered service provider; and
(ii) a statement as to whether the covered service provider continues to provide services to the plan.
[struck: (IV)] [inserted: (V)] A notice described in subclause (I)(cc) shall be filed with the Department not later than 30 days following the earlier of—
(aa) The covered service provider’s refusal to furnish the information requested by the written request described in subclause (I)(bb); or
(bb) 90 days after the written request referred to in subclause (I)(cc) is made.
(V) If the covered service provider fails to comply with the written request under subclause (I)(bb) within 90 days of such request, the responsible plan fiduciary shall determine whether to terminate or continue the contract or arrangement under section 1104 of this title. If the requested information relates to future services and is not disclosed promptly after the end of the 90-day period, the responsible plan fiduciary shall terminate the contract or arrangement as expeditiously as possible, consistent with such duty of prudence.
(ix) Nothing in this subparagraph shall be construed to supersede any provision of State law that governs disclosures by parties that provide the services described in this section, except to the extent that such law prevents the application of a requirement of this section.
§ 1108(b)Enumeration of transactions exempted from section 1106 prohibitions(2)–(3)
(b)(2)(B)(x)–(C)(vii) unchanged ·
(II) the terms “covered plan”, “covered service provider”, and “responsible plan fiduciary” have the meanings given such terms in subparagraph (B); and
(III) the terms “group health insurance coverage”, “health insurance coverage”, and “health insurance issuer” have the meanings given such terms in section 1191b of this title.
(C)
(i)
(I) [inserted: For plan years beginning on or after the date that is 30 months after the date of enactment of this subparagraph (referred to in this clause as the “effective date”), no contract or arrangement or renewal or extension of a contract or arrangement, entered into on or after the effective date, for services between a covered plan and a covered service provider, through a health insurance issuer offering group health insurance coverage, a third-party administrator, an entity providing pharmacy benefit management services, or other entity, for pharmacy benefit management services, is reasonable within the meaning of this paragraph unless such entity providing pharmacy benefit management services—]
(aa) [inserted: remits 100 percent of rebates, fees, alternative discounts, and other remuneration received from any applicable entity that are related to utilization of drugs or drug spending under such health plan or health insurance coverage, to the group health plan or health insurance issuer offering group health insurance coverage; and]
(bb) [inserted: does not enter into any contract for pharmacy benefit management services on behalf of such a plan or coverage, with an applicable entity unless 100 percent of rebates, fees, alternative discounts, and other remuneration received under such contract that are related to the utilization of drugs or drug spending under such group health plan or health insurance coverage are remitted to the group health plan or health insurance issuer by the entity providing pharmacy benefit management services.]
(II) [inserted: Nothing in subclause (I) shall be construed to affect the term of a contract or arrangement, as in effect on the effective date (as described in such subclause), except that such subclause shall apply to any renewal or extension of such a contract or arrangement entered into on or after such effective date, as so described.]
(ii) [inserted: With respect to such rebates, fees, alternative discounts, and other remuneration—]
(I) [inserted: the rebates, fees, alternative discounts, and other remuneration under clause (i)(I) shall be—]
(aa) [inserted: remitted—]
(AA) [inserted: on a quarterly basis, to the group health plan or the group health insurance issuer, not later than 90 days after the end of each quarter; or]
(BB) [inserted: in the case of an underpayment in a remittance for a prior quarter, as soon as practicable, but not later than 90 days after notice of the underpayment is first given;]
(bb) [inserted: fully disclosed and enumerated to the group health plan or health insurance issuer; and]
(cc) [inserted: returned to the covered service provider for pharmacy benefit management services on behalf of the group health plan if any audit by a plan sponsor, issuer or a third party designated by a plan sponsor, indicates that the amounts received are incorrect after such amounts have been paid to the group health plan or health insurance issuer;]
(II) [inserted: the Secretary may establish procedures for the remittance of rebates fees, alternative discounts, and other remuneration under subclause (I)(aa) and the disclosure of rebates, fees, alternative discounts, and other remuneration under subclause (I)(bb); and]
(III) [inserted: the records of such rebates, fees, alternative discounts, and other remuneration shall be available for audit by the plan sponsor, issuer, or a third party designated by a plan sponsor, not less than once per plan year.]
(iii) [inserted: To ensure that an entity providing pharmacy benefit management services is able to meet the requirements of clause (ii)(I), a rebate aggregator (or other purchasing entity designed to aggregate rebates) and an applicable group purchasing organization shall remit such rebates to the entity providing pharmacy benefit management services not later than 45 days after the end of each quarter.]
(iv) [inserted: A third-party administrator of a group health plan, a health insurance issuer offering group health insurance coverage, or a covered service provider for pharmacy benefit management services under such health plan or health insurance coverage shall make rebate contracts with rebate aggregators or drug manufacturers available for audit by such plan sponsor or designated third party, subject to reasonable restrictions (as determined by the Secretary) on confidentiality to prevent re-disclosure of such contracts or use of such information in audits for purposes unrelated to this section.]
(v) [inserted: Audits carried out under clauses (ii)(III) and (iv) shall be performed by an auditor selected by the responsible plan fiduciary. Payment for such audits shall not be made, whether directly or indirectly, by the entity providing pharmacy benefit management services.]
(vi) [inserted: Nothing in this subparagraph shall be construed to—]
(I) [inserted: prohibit reasonable payments to entities offering pharmacy benefit management services for bona fide services using a fee structure not described in this subparagraph, provided that such fees are transparent and quantifiable to group health plans and health insurance issuers;]
(II) [inserted: require a third-party administrator of a group health plan or covered service provider for pharmacy benefit management services under such health plan or health insurance coverage to remit bona fide service fees to the group health plan;]
(III) [inserted: limit the ability of a group health plan or health insurance issuer to pass through rebates, fees, alternative discounts, and other remuneration to the participant or beneficiary; or]
(IV) [inserted: modify the requirements for the creation, receipt, maintenance, or transmission of protected health information under the privacy regulations promulgated under the Health Insurance Portability and Accountability Act of 1996 in part 160 and subparts A and E of part 164 of title 45, Code of Federal Regulations (or successor regulations).]
(vii) [inserted: For purposes of this subparagraph—]
(I) [inserted: the terms “applicable entity” and “applicable group purchasing organization” have the meanings given such terms in section 726(e);]
(II) [inserted: the terms “covered plan”, “covered service provider”, and “responsible plan fiduciary” have the meanings given such terms in subparagraph (B); and]
(III) [inserted: the terms “group health insurance coverage”, “health insurance coverage”, and “health insurance issuer” have the meanings given such terms in section 733.]
(3) A loan to an employee stock ownership plan (as defined in section 1107(d)(6) of this title), if—
(A) such loan is primarily for the benefit of participants and beneficiaries of the plan, and
Rest of § 1108 unchanged ·
29 U.S.C. § 1132 Civil enforcement
3 changes the bill asks for here, 1 carried out
- Not carried out:
in subsection (a)(6), by striking
or (9)
and inserting(9), or (13)
;“or (9)” isn't in § 1132(a)(6) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“or (9)” not found in /us/usc/t29/s1132/a/6 - Not carried out:
in subsection (b)(3), by striking
under subsection (c)(9)
and insertingunder paragraphs (9) and (13) of subsection (c)
; and“under subsection (c)(9)” isn't in § 1132(b)(3) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“under subsection (c)(9)” not found in /us/usc/t29/s1132/b/3 - Carried out:
in subsection (c), by adding at the end the following:
(13) Secretarial enforcement authority relating to oversight of pharmacy benefit management services.— (A) Failure to provide information.— The Secretary may impose a penalty against a plan administrator of a group health plan, a health insurance issuer offering group health …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 1132(c)–(d)
Start of § 1132 to (c)(13)(A) unchanged ·
(B) False information.— The Secretary may impose a penalty against a plan administrator of a group health plan, a health insurance issuer offering group health insurance coverage, an entity providing pharmacy benefit management services, or an applicable entity (as defined in section 1185o(e) of this title) that knowingly provides false information under section 1185o of this title, in an amount not to exceed $100,000 for each item of false information. Such penalty shall be in addition to other penalties as may be prescribed by law.
(C) Waivers.— The Secretary may waive penalties under subparagraph (A), or extend the period of time for compliance with a requirement of this section, for an entity in violation of section 1185o of this title that has made a good-faith effort to comply with the requirements of section 1185o of this title.
(13) [inserted: Secretarial enforcement authority relating to oversight of pharmacy benefit management services.—]
(A) [inserted: Failure to provide information.—] [inserted: The Secretary may impose a penalty against a plan administrator of a group health plan, a health insurance issuer offering group health insurance coverage, or an entity providing pharmacy benefit management services on behalf of such a plan or issuer, or an applicable entity (as defined in section 726(f)) that violates section 726(a); an entity providing pharmacy benefit management services on behalf of such a plan or issuer that fails to provide the information required under section 726(b); or any person who causes a group health plan to fail to provide the information required under section 726(c), in the amount of $10,000 for each day during which such violation continues or such information is not disclosed or reported.]
(B) [inserted: False information.—] [inserted: The Secretary may impose a penalty against a plan administrator of a group health plan, a health insurance issuer offering group health insurance coverage, an entity providing pharmacy benefit management services, or an applicable entity (as defined in section 726(f)) that knowingly provides false information under section 726, in an amount not to exceed $100,000 for each item of false information. Such penalty shall be in addition to other penalties as may be prescribed by law.]
(C) [inserted: Waivers.—] [inserted: The Secretary may waive penalties under subparagraph (A), or extend the period of time for compliance with a requirement of this section, for an entity in violation of section 726 that has made a good-faith effort to comply with the requirements of section 726.]
(d) Status of employee benefit plan as entity
(1) An employee benefit plan may sue or be sued under this subchapter as an entity. Service of summons, subpena, or other legal process of a court upon a trustee or an administrator of an employee benefit plan in his capacity as such shall constitute service upon the employee benefit plan. In a case where a plan has not designated in the summary plan description of the plan an individual as agent for the service of legal process, service upon the Secretary shall constitute such service. The Secretary, not later than 15 days after receipt of service under the preceding sentence, shall notify the administrator or any trustee of the plan of receipt of such service.
Rest of § 1132 unchanged ·